Contribution of PET Studies in Diagnosis of Corticobasal DegenerationLutte I.a · Laterre C.a · Bodart J.-M.b · De Volder A.b
aNeurology Service, Cliniques St. Luc, Louvain-en-Woluwe, and bPositron Tomography Laboratory, Université Catholique de Louvain, Louvain-la-Neuve, Belgium
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Five patients with clinical features of corticobasal degeneration (CBD) were studied with PET imaging. The main clinical findings included a unilateral extrapyramidal motor disorder, without significant response to levodopa, as well as clumsiness, dysarthria, apraxia and a clear asymmetry of neurological signs. PET studies with 18F-labeled 2-deoxy-2-fluoro-D-glucose disclosed mainly a significant hypometabolism in the thalamus and motor cortex controlateral to the more affected limbs. Additional relationships between individual clinical signs and PET data were also found. We concluded that PET findings supported the clinical diagnosis of CBD, although the specific pattern related to this condition needs to be more precisely defined. Further studies are especially needed to correlate clinical data and PET results with pathological examination.
© 2000 S. Karger AG, Basel
- Rebeiz JJ, Kolodny EH, Richardson EP: Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20–33.
Case Records of the Massachusetts General Hospital: Weekly clinicopathological exercices. Case 38-1985. A 66-year-old man with progressive neurologic deterioration. N Engl J Med 1985;313:739–748.
- Clark AW, Manz HJ, White CL 3d, Lehmann J, Miller D, Coyle JT: Cortical degeneration with swollen chromatolytic neurons: Its relationship to Pick’s disease. J Neuropathol Exp Neurol 1986;45:268–284.
- Gibb WRG, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989;112:1171–1192.
- Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, et al: Cortico-basal ganglionic degeneration. Neurology 1990;40:1571–1578.
Thompson PD, Marsden CD: Corticobasal degeneration. Baillière’s Clin Neurol 1992;677–685.
- Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I: Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015–2019.
- Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Brancher C, Tabaton M, Kellinger K, Anderson DW: Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders. J Neuropathol Exp Neurol 1996;55:97–105.
- Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD: The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110–118.
- Jones WF, Digby WM, Luk WK, Casey ME, Byars LG: Optimizing rod window width in positron emission tomography. IEEE Trans Med Imag 1995;14:266–270.
- Hamacher K, Coenen HH, Stöcklin G: Efficient stereospecific synthesis of no-carrier- added 2-[F-18]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235–238.
- Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Würker M, Heiss WD: An interactive technique for three-dimensional image registration: Validation for PET, SPECT, MRI, and CT brain studies. J Nucl Med 1994;35:2011–2018.
Michel C, Sibomana M, Bodart JM, Grandin C, Coppens A, Bol A, De Volder A, Warscotte V, Thiran JP, Macq B: Interactive delineation of brain sulci and their merging into functional PET images; in Moonier PA (ed): Proceedings of IEEE Medical Imaging Conference, vol 3. San Francisco, IEEE Service Center, 1995, pp 1480–1484.
- Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with [F18]-2-fluoro-2-deoxy-D-glucose: Validation of the method. Ann Neurol 1979;6:371–388.
- Coppens A, Sibomana M, Bol A, Michel C: MEDIMAN: An object oriented programming approach for medical image analysis. IEEE Trans Nucl Sci 1993;40:950–955.
- Goffinet AM, De Volder AG, Gillain C, Rectem D, Bol A, Michel C, Cogneau C, Labar D, Laterre C: Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 1989;25:131–139.
- De Volder AG, Francart J, Laterre C, Dooms G, Bol A, Michel C, Labar D, Goffinet AM: Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989;26:239–247.
- Weiller C, Chollet F, Friston KJ, Wise RJS, Frackowiak RSJ: Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann Neurol 1992;31:463–472.
Watts RL, Williams RS, Growdon JD, Young RR, Haley EC, Beal MF: Cortico-basal ganglionic degeneration (abstract). Neurology 1985;35(suppl 1):178.
Watts RL, Mirra SS, Young RR, Burger PC, Villier JA, Heyman A: Cortico-basal ganglionic degeneration (CBGD) with neuronal achromasia: Clinical-pathological study of two cases (abstract). Neurology 1989;39(suppl 1):140.
- Greene PE, Fahn S, Lang AE, Watts RL, Eidelberg D, Powers JM: What is it? Case 1, 1990. Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. Mov Disord 1990;5:341–351.
- Lippa CF, Smith TW, Fontneau N: Corticonigral degeneration with neuronal achromasia. A clinicopathologic study of two cases. J Neurol Sci 1990;98:301–310.
- Paulus W, Selim M: Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles (review). Acta Neuropathol (Berl) 1990;81:89–94.
- Sawle GV, Brooks DJ, Marsden CD, Frackoviack RSJ: Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991;114:541–556.
Rinne JO, Lee MS, Thompson PD, Marsden CD: Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;177:1183–1196.
Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, Cederbaum J, Greene P, Fahn S, Powers JM, Rottenberg DA: The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;17:337–343.
- Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS: Corticobasal degeneration: Neuropathologic and clinical heterogeneity. Neurology 1997;48:959–969.
- Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, Greene PE, Prezdborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Mlho ES, Riley DE: Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957–961.
- Brown J, Lantos PL, Roques P, Fidani L, Rossor MN: Familial Pick’s syndrome with swollen achromatic neurons and corticobasal inclusion bodies: A clinical and pathological study. J Neurol Sci 1996;135:21–30.
Tissot R, Constantinidis J, Richard J; in Vinken PJ, Bruyn GW, Klawans HL (eds): Handbook of Clinical Neurology. Amsterdam, Elsevier, 1985, vol 46, pp 233–246.
Kidron D, Melamed E: Study of various forms in patients with Parkinson’s disease. Neurology 1986;36(suppl 1):216.
- LeWitt PA, Burns RS, Newman RP: Dystonia in untreated parkinsonism. Clin Neuropharmacol 1986;9:293–297.
- Rivest J, Quinn NP, Marsden CD: Dystonia in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurology 1990;40:1571–1578.
- Vidailhet M, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Gaymard B, Agid Y, Pierrot-Deseilligny C: Eye movements in parkinsonian syndromes. Ann Neurol 1994;35:420–426.
- Smith-Doody R, Jankovic J: The alien hand and related signs. J Neurol Neurosurg Psychiatry 1992;55:806–810.
- Ball JA, Lantos PL, Jackson M, Marsden CD, Scadding JW, Rossor MN: Alien hand sign in association with Alzheimer’s histopathology. J Neurol Neurosurg Psychiatry 1993;56:1020–1023.
- Golberg G, Mayer MH, Toglia JU: Medial frontal cortex infarction and the alien hand sign. Arch Neurol 1981;38:683–686.
- Crystal HA, Horoupian DS, Katzman R, Jotkowitz S: Biopsy-proven Alzheimer disease presenting as a right parietal lobe syndrome. Ann Neurol 1982;12:186–188.
- Jagust WJ, Davies P, Tiller-Borcich JK, Reed BR: Focal Alzheimer’s disease. Neurology 1990;40:14–19.
- Lang AE, Bergeron C, Pollanen MS, Ashby P: Parietal Pick’s disease mimicking cortico-basal ganglionic degeneration. Neurology 1994;44:1436–1440.
Cambier J, Masson M, Dairou R, Henin D: Etude anatomo-clinique d’une forme pariétale de maladie de Pick. Rev Neurol 1981;137:33–38.
Blein J, Vidhaillet MJ, Pillon B, Dubois B, Feve JR, Agid Y: Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1991;7:348–354.
Eidelberg D, Moeller JR, Sidtis JJ, Dahwan V, Strother SC, Fahn S, Rottenberg DA: Corticodentatonigral degeneration: Metabolic asymmetries studied with F-fluorodeoxyglucose and positron emission tomography. Neurology 1989;39(suppl 1):164.
Nagasawa H, Imamura T, Nomura H, Itoh M, Ido T: A case of corticobasal degeneration studied with positron emission tomography. Behav Neurol 1993;6:59–64.
- Brunt ER, van Weerden TW, Pruim J, Lakke JW: Unique myoclonic pattern in corticobasal degeneration. Mov Disord 1995;10:132–142.
Nagahama Y, Fukuyama H, Turjanski N, Kennedy A, Yamauchi H, Ouchi Y, Kimura J, Brooks DJ, Shibasaki H: Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. Mov Disord 1991;114:541–556.
- Taniwaki T, Yamada T, Yoshida T, Sasaki M, Kuwabara Y, Nakagawa M, Mihara F, Motomora S, Shigetou H, Kira J: Heterogeneity of glucose metabolism in corticobasal degeneration. J Neurol Sci 1998;161:70–76.
- Freund HJ, Hummelsheim H: Lesions of premotor cortex in man. Brain 1985;108:697–733.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.